Stifel Nicolaus Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)
JPMorgan Adjusts Price Target on Nurix Therapeutics to $34 From $31, Maintains Overweight Rating
Nurix Therapeutics Analyst Ratings
Barclays Sticks to Its Buy Rating for Nurix Therapeutics (NRIX)
Needham Adjusts Price Target on Nurix Therapeutics to $29 From $31, Maintains Buy Rating
Nurix Therapeutics (NRIX) Receives a Buy From Wells Fargo
Piper Sandler Remains a Buy on Nurix Therapeutics (NRIX)
Nurix Therapeutics Analyst Ratings
Nurix Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $26
Nurix Therapeutics Analyst Ratings
Nurix Therapeutics Analyst Ratings
Nurix Therapeutics Gains Buy Rating Amid Strong Clinical Advances for CLL Drug NX-5948
Nurix Therapeutics Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: Unicycive Therapeutics (UNCY), Nurix Therapeutics (NRIX)
Nurix Therapeutics Analyst Ratings
Analysts' Top Healthcare Picks: Evolent Health (EVH), Nurix Therapeutics (NRIX)
Analysts Offer Insights on Healthcare Companies: Evogene (EVGN), Edwards Lifesciences (EW) and Nurix Therapeutics (NRIX)
RBC Lifts Price Target on Nurix Therapeutics to $23 From $22, Keeps Outperform Rating, Speculative Risk Qualifier
Nurix Therapeutics Analyst Ratings